|
PrNEUPOGEN® Reimbursement
NEUPOGEN® (filgrastim)
DIN 01968017
NEUPOGEN® is an eligible benefit through most private insurance plans, provincial/ territorial drug benefit programs and federal drug plans. Please choose the appropriate drug plan/program from the sidebar menu for specific information on NEUPOGEN® reimbursement.
Indications:
Cancer Patients Receiving Myelosuppressive Chemotherapy
NEUPOGEN® (filgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies (see PATIENTS WITH ACUTE MYELOID LEUKEMIA* in the Product Monograph) receiving myelosuppressive anti-neoplastic drugs.
NEUPOGEN® is indicated in adult and pediatric patients with cancer receiving myelosuppressive chemotherapy.
A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy, and twice per week (see LABORATORY MONITORING* in the Product Monograph) during NEUPOGEN® therapy to avoid leukocytosis and to monitor the neutrophil count.
In phase 3 clinical studies, NEUPOGEN® therapy was discontinued when the ANC was > 10 x 10 9/L after expected chemotherapy-induced nadir.
Patients with Acute Myeloid Leukemia
NEUPOGEN® is indicated for the reduction in the duration of neutropenia, fever, antibiotic use and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.
Cancer Patients Receiving Myeloablative Chemotherapy Followed by Bone Marrow Transplantation
NEUPOGEN® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients undergoing myeloablative therapy followed by bone marrow transplantation.
A CBC and platelet count should be obtained at a minimum of 3 times per week
following marrow infusion to monitor marrow reconstitution (see LABORATORY MONITORING* in the Product Monograph).
Cancer Patients Undergoing Peripheral Blood Progenitor Cell (PBPC) Collection and Therapy
NEUPOGEN® is indicated for the mobilization of autologous peripheral blood progenitor cells in order to accelerate haematopoietic recovery by infusion of such cells, supported by NEUPOGEN®, after myelosuppressive or myeloablative chemotherapy (see CLINICAL EXPERIENCE* in the Product Monograph).
Patients with Severe Chronic Neutropenia
NEUPOGEN® is indicated for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infection in patients with a diagnosis of congenital, cyclic or idiopathic neutropenia (see CLINICAL EXPERIENCE* in the Product Monograph).
Patients with HIV Infection
NEUPOGEN® is indicated in patients with HIV infection for the prevention and treatment of neutropenia, to maintain a normal ANC (e.g., between 2 x 10 9 and 10 x 10 9/L). NEUPOGEN® therapy reduces the clinical sequelae associated with neutropenia (e.g., bacterial infections) and increases the ability to deliver myelosuppressive medications used for the treatment of HIV and its associated complications (see CLINICAL EXPERIENCE* in the Product Monograph). It is recommended that complete blood counts and platelet counts be monitored at regular intervals (e.g., initially twice weekly for 2 weeks, once weekly for an additional 2 weeks, then once monthly thereafter, or as clinically indicated) during NEUPOGEN® therapy (see LABORATORY MONITORING* in the Product Monograph).
Contraindications
NEUPOGEN® (filgrastim) is contraindicated in patients with known hypersensitivity to E. coli-derived products or to any component of the product. For a complete listing of the components, see the Dosage Forms, Composition and Packaging section of the product monograph.
Warnings and Precautions
Serious Warnings and Precautions
Splenic rupture, including fatal cases, has been reported following the administration of NEUPOGEN® (see WARNINGS AND PRECAUTIONS: General of the product monograph).
Severe sickle cell crises, in some cases resulting in death, have been associated with the use of NEUPOGEN® in patients with sickle cell disorders (see WARNINGS AND PRECAUTIONS: Hematologic of the product monograph).
NEUPOGEN® Product Monograph
Resources for Healthcare Professionals and Patients
The following websites are external links. DrugCoverage assumes no responsibility for the content of these sites.
NEUPOGEN® Product Monograph
National Comprehensive Cancer Network (NCCN) Website (requires password / login)
Once logged in, click on NCCN Clinical Practice Guidelines in OncologyTM.
Scroll down to "guidelines for Supportive Care" to find:
Myeloid Growth Factors V.1. 2011
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence Based Clinical Practice Guideline
Smith, Thomas J., Khatcherssian, James, Lyman, Gary H. (2006)
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 24 (19): 3187 - 3205
Amgen Canada's VICTORYTM Program provides reimbursement information and assistance 24 hours a day, 7 days per week to patients with a prescription for NEUPOGEN ®. Financial assistance may be available to eligible patients in accordance with criteria established by the VictoryTM Program, which may change at anytime without prior notice in the Program's sole discretion. Call 1-888-706-4717 to enroll.
VICTORYTM Program Patient Enrollment Form
|
